Intravascular ultrasound versus angiogram guided drug eluting stent implantation. A systematic review and updated meta-analysis with trial sequential analysis

Ashish Kumar a, Mariam Shariff a, Devina Adalja b, Rajkumar Doshi c,⁎

a Department of Critical Care Medicine, St John’s Medical College Hospital, Bengaluru, Karnataka, India
b Department of Medicine, Gotri Medical Education and Research Centre, Vadodara, Gujarat, India
c Department of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV, USA

ABSTRACT

Background: Further advances have been achieved in the field of intravenous ultrasound (IVUS) guided drug eluting stent (DES) implantation and hence there was a need to rejuvenate the evidence. Hence, we performed a cumulative meta-analysis with trial sequential analysis (TSA) of randomized controlled trials (RCTs) comparing IVUS versus angiogram guided DES implantation.

Methodology: We searched PubMed/Medline and Cochrane database for relevant articles using predefined inclusion and exclusion criteria. Outcomes of interest were cardiovascular mortality, myocardial infarction (MI), target lesion revascularisation (TLR), stent thrombosis (ST). We used Mantel-Haenszel method with random error model to calculate odds ratio (OR) with 95% confidence interval (CI). We also performed TSA to accommodate for possible type I error.

Results: A total of 11 RCTs with 5352 patients were included in the final analysis. Follow up duration of included studies varied from 12 to 24 months. IVUS use was associated with significantly reduced incidence of cardiovascular mortality [OR: 0.45, CI: 0.25–0.80, p value = 0.007, I² = 0%, χ² p-value = 0.98], TLR [OR: 0.56, CI: 0.41–0.77, p value = 0.0004, I² = 0%, χ² p-value = 0.95] and ST [OR: 0.47, CI: 0.24–0.94, p value = 0.03, I² = 0%, χ² p-value = 0.75]. IVUS use had no effect on incidence of MI on follow up. The cumulative z curve crosses the TSA boundary indicating sufficient evidence without type I error for reduced incidence of cardiovascular mortality and TLR with the use IVUS.

Conclusion: IVUS-guided DES implantation should be the standard of care as it significantly reduced cardiovascular mortality and TLR.

© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: IVUS, DES, Meta-analysis, Trial sequential analysis, TLR, Stent thrombosis

1. Introduction

Drug eluting stent (DES) implantation has emerged as a standard treatment in patients undergoing percutaneous coronary intervention for acute coronary syndrome [1]. However, use of DES is associated with target lesion revascularisation (TLR) and stent thrombosis (ST), which persists as a substantial concern [2]. Trials are under way to procure approaches engendering improved outcomes with DES implantation. Several randomized control trials (RCTs) have documented better long-term clinical outcomes associated with the use of intravascular ultrasound (IVUS) as compared to angiogram-guided DES implantation [3,4]. The current recommendations for the use of IVUS-guided DES implantation are based on observational studies [5]. Previous meta-analysis of RCTs studying the role IVUS guided DES implantation have not analysed or commented regarding the power of their evidence. Also, further advances have been achieved in the field of IVUS guided DES implantation, and hence, there was a need to rejuvenate the evidence. Hence, we performed an updated meta-analysis with trial sequential analysis of RCTs comparing IVUS versus angiogram guided DES implantation.

2. Methodology

The meta-analysis was performed according to the PRISMA (preferred reporting items for systematic review) and AHA (American heart
association) guidelines [6,7]. Medline/PubMed and Cochrane databases were used to search relevant articles from inception to April 2019. The search terms used included “intravascular ultrasound”, “IVUS”, “angiogram”, “Drug eluting stent”, “DES”, “Percutaneous coronary intervention”, “PCI”. The identified citations were imported to Mendeley reference manager. A manual search for relevant citations form bibliographies of articles and reviews was performed. We checked for any duplicates among the citations included using the Mendeley reference manager.

Articles were eligible for inclusion if they met the following inclusion criteria, 1) RCTs studying IVUS versus angiogram guided DES (Both first and second generation) implantation, from inception to April 2019, with no restriction on sample size or language of the published article. 2) Manuscripts reporting either one of the following four outcomes: a) Cardiovascular Mortality, b) Myocardial infarction (MI), c) TLR or d) ST.

Two reviewers AK and MS independently performed data extraction. Any disparity was resolved by mutual consensus and in consultation with the senior author RD. The data was extracted as per a predesigned data extraction form. The following data was extracted from each article; author’s first name/Trial name, year of publication, study design, duration of study, mean age of the population, percentage male, number randomized, mean of minimum luminal diameter and percentage diameter stenosis between the two groups, number of the following events in the two groups a) Cardiovascular mortality, b) MI, c) TLR and d) definite/probable ST.

The analysis was carried out using RevMan Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). For statistical analysis we used Mantel-Haenszel method with random error model to calculate odds ratio (OR) with 95% confidence interval (CI). Heterogeneity was assessed using the I² test >60% or χ² p-value <0.05. We used the funnel plot to assess for publication bias visually. We refrained from using Egger’s test to statistically report asymmetry in the funnel plot because of small number of included studies.

We performed trial sequential analysis (TTA) on outcomes, to accommodate for increased risk of type I error resulting from repeated significance testing because of the addition of new trials in a meta-analysis. Ergo trials sequential analysis helps in eliminating the possibility of type I error from the final estimate [8]. TSA for MI was not generated as the results were not in favour of either arm.

3. Results

We included 11 RCTs comparing IVUS versus angiogram guided DES implantation [3,4,9–17]. The PRISMA flow diagram is shown in Supplementary Fig. 1. The baseline characteristics of included studies are mentioned in Supplementary Table 1. Pooled estimates were calculated for cardiovascular mortality, MI, TLR and ST. The analysis included a total of 5,352 patients. The follow up period varied from 12 to 24 months among RCTs. The weighed mean follow up was 13.68 months.

3.1. Cardiovascular mortality

IVUS-guided DES implantation resulted in significantly reduced incidence of cardiovascular mortality [OR: 0.45, CI: 0.25–0.80, p value = 0.007, I² = 0%, χ² p-value = 0.98] [Fig. 1, Panel A]. There was no heterogeneity associated with the pooled estimation as suggested by I² = 0% and χ² p-value = 0.89. Supplementary Fig. 2 represents the funnel plot for assessing publication bias for cardiovascular mortality outcome, indicates publication bias. TSA adjusted confidence interval for alpha error of 5% and beta error of 20% was 0.24–0.84. (Fig. 2, Panel A). The cumulative z curve crosses the TSA boundary indicating sufficient evidence without significant type I error for reduced incidence of cardiovascular mortality.

3.2. Myocardial infarction

The incidence of MI was lower following IVUS-guided DES implantation, however, the association was not statistically significant [OR: 0.83, CI: 0.54–1.28, p value = 0.39, I² = 0%, χ² p-value = 0.69] (Fig. 1, Panel B). Supplementary Fig. 3 demonstrates the funnel plot, assessing publication bias for reporting of MI outcome, denotes minimal publication bias.

3.3. Target lesion revascularisation

IVUS-guided DES implantation was associated with a lower incidence of TLR on follow up [OR: 0.56, CI: 0.41–0.77, p value = 0.0004, I² = 0%, χ² p-value = 0.95] (Fig. 1, Panel C). Supplementary Fig. 4 represents the funnel plot, denoting publication bias more than minimal. TSA adjusted confidence interval for alpha error of 5% and beta error of 20% was 0.40–0.79. (Fig. 2, Panel B). As evident from the figure that the cumulative z curve crosses TSA boundary indicating the outcome is associated with an acceptable level of type I error.

3.4. Stent thrombosis

IVUS-guided DES implantation significantly reduced the incidence of ST [OR: 0.47, CI: 0.24–0.94, p value = 0.03, I² = 0%, χ² p-value = 0.75] (Fig. 1, Panel D). Supplementary Fig. 5 represents the funnel plot for ST outcome, indicates possibility of minimal publication bias. TSA adjusted confidence interval for alpha error of 5% and beta error of 20% was 0.20–1.13. (Fig. 2, Panel C). The decreased incidence of ST is therefore associated with an increased risk of type I error as evident from TSA plot and TSA adjusted confidence interval.

4. Discussion

The results of this meta-analysis concluded that IVUS as compared to angiogram guided DES implantation resulted in a lower incidence of cardiovascular mortality. TLR and ST. IVUS-guided DES implantation, although resulted in a lower incidence of MI, the association was not statistically significant. A recently published meta-analysis compared IVUS versus angiogram guided DES implantation [18]. The present meta-analysis augments the evidence in the field as compared to the previous meta-analysis by the addition of one more randomized control trial [15], reporting no statistically significant drop in incidence of MI with IVUS-guided DES implantation and TSA of outcomes. The discovery of no statistically significant lowering in the incidence of MI with DES implantation in the present meta-analysis is also contrary to a previously published patient-level meta-analysis of 2345 procedures [19]. Furthermore, this meta-analysis included TSA of outcomes not depicted in earlier meta-analyses. This meta-analysis demonstrated that the strength of evidence for outcomes a) Cardiovascular mortality and b) TLR were sufficient without the risk of type I error. However, ST was associated with a risk of type I error as evident from TSA.

IVUS helps in overcoming many limitations of angiogram, which produces a two dimensional lumenogram of a three dimensional structure. IVUS helps to determine plaque burden, calcium and eccentricity, and stent expansion [20]. IVUS during PCI can also be used to determine stent size, identify optimal proximal and distal stent edge landing zones. [21]. The AVIO trial which studied the use of IVUS as compared to angiogram for DES implantation for complex coronary lesions, a benefit was observed with IVUS in complex lesion in post procedural minimum lumen diameter, which is one of the important determinant of late complications [13]. Two recent RCTs also demonstrated that IVUS-guided implantation resulted in increased acute gain and late lumen loss when compared with angiography guided implantation [13] [15]. Clinical benefit with these improvements was further confirmed in the ULTIMATE trial [16]. IVUS-
Fig. 1. Forest plot for a) Panel A- cardiovascular mortality, b) Panel B- myocardial infarction, c) Panel C- target lesion revascularisation, d) Panel D- stent thrombosis. IVUS- intravascular ultrasound, OR- odds ratio, CI- confidence interval.
Fig. 2. TSA plot for a) Panel A – cardiovascular mortality, b) Panel B – target lesion revascularisation, c) Panel C – stent thrombosis. IVUS – intravascular ultrasound.
stent implantation has the additional advantage of being associated with minimal complications in patients with renal disease, as it does not require the administration of contrast [22]. However, IVUS-guided stent placement has a steep learning curve and requires a certain level of clinical expertise. As per a study using the national inpatients sample [NIS] the number of IVUS guided PCI procedures did not change significantly from −5% in 2007 to −6.5% in 2013. They also reported a heterogeneity in IVUS utilization across institutions [23]. Training program directors may consider intravascular imaging (either IVUS or optical coherence tomography) to be a part of a fellows’ curriculum. At present there is class IIb evidence for the use of IVUS for coronary stent implantation [20]. Hopefully, this along with other recently published meta-analyses can help change the guidelines.

There are several limitations in our meta-analysis. The results of this meta-analysis should be considered with caution, keeping in mind the possibility of publication bias. Each included RCT is associated with different study design and biases, which has not been addressed in this analysis. Type and site of the lesion were not determined, and hence, these results cannot be generalized. Few larger trials may have influenced the results of this study. Non-adherence to anti-platelet therapy is also one of the most important reasons for ST. This information was not available as with any meta-analysis. Definitions of outcomes varied in different RCTs. Future studies considering patient level meta-analysis would help augment the present available evidence. The randomized trials included in this analysis had a heterogeneous patient sample, for example: all comers; patient with chronic total occlusion, STEMI, NSTEMI etc. Furthermore, the analysis didn’t account for different period of follow-up among studies during pooled estimation.

In conclusion, IVUS-guided DES implantation significantly reduces cardiovascular mortality and TLR without type I error. It also reduced ST, albeit with type I error and requires more studies to confirm it. IVUS-guided DES implantation should be the standard of care, especially for complex coronary lesions. Hopefully, this study will guide IVUS-guided new-generation drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study. EuroIntervention. 10 (2014) 1409–1417. https://eurointervention.rs/issue/angiographic-and-clinical-comparisons-of-intravascular-ultrasound-versus-angiography-guided-drug-eluting-stent-implantation-for-patients-with-chronic-total-occlusion-lesions-two-year-results-from-a-randomised.

[1] R. Piccolo, K.H. Bonaa, O. Efthimiou, O. Varenne, A. Baldo, P. Urban, C. Kaiser, R. Piccolo, K.H. Bonaa, O. Efthimiou, O. Varenne, A. Baldo, P. Urban, C. Kaiser, W. Remkes, L. Räber, A. de Belder, A.W.J. van’t Hof, G. Stankovic, P.A. Tian, S.-K. Gami, F. Ye, J.-J. Zhang, Z.-Z. Liu, S. Ge, S.-J. Shan, W. You, L. Chen, Y.-Z. Zhang, G.S. Mintz, S.-L. Chen, Angiographic and clinical comparisons of intravascular ultrasound and angiography-guided drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study, EuroIntervention. 10 (2014) 1409–1417. https://eurointervention.rs/issue/angiographic-and-clinical-comparisons-of-intravascular-ultrasound-versus-angiography-guided-drug-eluting-stent-implantation-for-patients-with-chronic-total-occlusion-lesions-two-year-results-from-a-randomised.

[2] T. Palmerini, G. Biondi-Zoccai, D.G. Alfonso, J. Terzic, M.D. Mulrow, P.C. Gatzke, J.P.A. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ 339 (2009) b2700, https://doi.org/10.1136/bmj.339.b2700.

[3] R. Gourash, J.-L. Francisco, B. Jack, D. Frank, D.N. H. H.M. A. H. George, K. Katherine, M. Christopher, P.-W.T. M. S. E. W. P. C. W. Jüni, W. Jennifer, Methodological requirements for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: a scientific statement from the American Heart Association, Circulation 136 (2017) e172−e194, https://doi.org/10.1161/CIR.0000000000000523.

[4] J. Wetterson, J.C. Jakobsen, C. Gluud, Trial sequential analysis in systematic reviews with meta-analysis, BMC Med. Res. Methodol. 17 (2017) 39, https://doi.org/10.1186/s12874-017-0315-7.

[5] J.-S. Kim, T.-S. Kang, G.S. Mintz, B.-E. Park, D.-H. Shin, B.-K. Kim, Y.-C. Ko, D. Choi, Y. Kang, M.-K. Hong, Randomized comparison of clinical outcomes between intravascular ultrasound and angiography-guided drug-eluting stent implantation for long coronary artery stenoses, JACC Cardiovasc. Interv. 6 (2013) 369–376, https://doi.org/10.1016/j.jcin.2012.11.009.

[6] A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P.A. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ 339 (2009) b2700, https://doi.org/10.1136/bmj.339.b2700.
[21] P. Das, I. Meredith, Role of intravascular ultrasound in unprotected left main percutaneous coronary intervention, Expert. Rev. Cardiovasc. Ther. 5 (2007) 81–89, https://doi.org/10.1586/14779072.5.1.81.

[22] A. Funatsu, Y. Hano, T. Kobayashi, S. Nakamura, TCT-348 efficacy of intravascular ultrasound guided minimum contrast percutaneous coronary intervention for chronic kidney disease patients, J. Am. Coll. Cardiol. 64 (2014) B101, https://doi.org/10.1016/j.jacc.2014.07.395.

[23] I.Y. Elgendy, L.D. Ha, A. Elbadawi, G.O. Ogunbayo, O. Olorunfemi, A.N. Mahmoud, M.K. Mojadadi, A. Abuzaid, R.D. Anderson, A.A. Bavry, Temporal trends in inpatient use of intravascular imaging among patients undergoing percutaneous coronary intervention in the United States, JACC Cardiovasc. Interv. 11 (2018) 913 LP–915, https://doi.org/10.1016/j.jcin.2018.01.254.